ABSTRACT
INTRODUCTION
Muscarinics, such as pilocarpine and carbachol, have been used topically as ocular hypotensive agents for more than a century (1) (2) (3) . They lower intraocular pressure (IOP) presumably by contracting the ciliary muscle (4) , which in turn increases the trabecular outflow of aqueous humor.
Topical administration of cholinergic agonists is safe.
Due to the low systemic concentration of the drug after topical uses, systemic side effects rarely occur (3) . However, ocular side effects of muscarinic agonists are common, which limits the acceptability of these compounds. Adverse reactions to pilocarpine and carbachol include miosis (due to the contraction of the iris sphincter), myopia (contraction of the ciliary muscle), temporal and supraorbital headache (supposedly secondary to the contraction of the ciliary muscle).
Attempts, such as the exploitation of pharmacokinetic properties of the compounds, have been made to minimize these side effects, with only limited success. However, there is recent evidence suggesting that separation of the IOP-lowering effect and ocular side effects of cholinergics is feasible. For example, aceclidine, another muscarinic agonist, is as effective and potent as pilocarpine at lowering IOP in humans, but is much more potent as a miotic and does not produce much accommodation (5) (6) (7) (8) . In the monkey, aceclidine also increases facility of aqueous outflow with minimal accommodative effect (9) .
Furthermore, in the monkey, the increase in outflow facility produced by pilocarpine was reversed by atropine in two phases, a fast phase and a slow one. Yet the reversal of accommodation exhibited only a fast phase (10) . This separation of muscarinic effects could be explained by the presence of different muscarinic receptor subtypes, each of which mediates different actions of the agonists.
Indeed, during the last several years, messenger RNAs of five muscarinic receptor subtypes were discovered (11, 12) . They are named ml to m5, in which ml, m2 and m3 correspond to the Ml, M2 and M3 receptor subtypes that were defined by affinity profiles of selective antagonists. Since (13) (14) (15) (16) (17) . In this report we used the cultured human ciliary muscle cells and attempted to elucidate the muscarinic receptor subtype that mediates the carbachol-induced contraction of the muscle cells as well as the activation of phospholipase C (PLC).
METHODS

Cell Culture
Human ciliary muscle cells were isolated and characterized as described earlier (18) . The 5 min prior to agonists. At the indicated time after the agonist was added, the reaction was stopped by replacing the medium with 0.5 ml of 5% perchloric acid (Baker, Philipsburg, NJ) . Samples were placed on ice for at least 10 min. The perchloric acid was removed from the cell lysate by extraction with 2 ml 1:1 mixture of 1,1,2-trichloro-trifluoro-ethane (Sigma):tri-n-octylamine (Sigma). After extraction, the aqueous layer was loaded onto 1 ml columns of formate-equilibrated BioRad AG 1x8 anion exchange resin (BioRad, Richmond, CA) . The columns were washed with 10 ml of water, followed by 8 ml of 50 mM formic acid (Sigma). The bound inositol phosphates were eluted with 4 ml of 1.2 M ammonium formate (Sigma) in 0.1 M formic acid and the incorporated tritium was monitored by scintillation counting. In recent experiments, this assay procedure was simplified such that the reaction was stopped by replacing the cell medium with 0.5 ml of 50 mM formic acid instead of perchloric acid. The cell lysate was then directly loaded onto the anion exchange column and eluted as described. The two assay procedures generated similar results. 
RESULTS
Cell Contraction
As shown in Figure 1 , the cross-sectional surface areas of most of the human ciliary muscle cells decreased 5 and 10 min after carbachol (100 pM) treatment (Fig. 3) . (Fig. 3B) . Effects of higher concentrations of carbachol were antagonized by increasing amounts of 4DAMP ( Fig. 3C and 3D ) . Dose response relationship of carbachol in the presence of various concentrations of 4DAMP summarizes these results (Fig. 5, upper panel) Accordingly, in the contraction assay, 4DAMP was a much more potent antagonist than pirenzepine. Based on the affinity profiles of these selective antagonists, the M3 or an M3-like receptor subtype was essential in the carbachol-induced activation of PLC and cell contraction. These findings agree with the published data in that the M3 receptor is important for functions of the ciliary muscle. In the human ciliary muscle, by using autoradiography and in situ hybridization, Gupta et al showed that ml/Ml and m3/M3 receptor subtypes are present (14) . The messenger RNA of the m3 receptor was detected by Northern blot in the cultured human ciliary muscle cells and post mortem tissue (13, 15) . Furthermore, WoldeMussie et al (17) demonstrated that the muscarinic binding sites in these cells were most likely M3 receptors and, similar to our findings, the muscarinic agonist-induced PLC activation was mediated by an M3-like receptor. Interestingly, the m3/M3 receptor is also shown to be the most common muscarinic receptor subtype in the iris sphincter (14, 17) , implying that this receptor likely mediates the muscarinic agonist-induced miosis. Indeed, Gabelt and Kaufman (16) receptor mediates muscarinic agonist-induced contractions of both the iris sphincter and the ciliary smooth muscles. If it is proven true, separation of the IOPlowering effect and the ocular side effects of muscarinic compounds by using receptor subtype selective agonists will be theoretically impossible.
This conclusion cannot reconcile with findings that aceclidine has different potencies for miosis, accommodation and outflow facility (5) (6) (7) (8) (9) . It may also contradict the apparent two-component mode of the pilocarpine-induced increase in aqueous outflow facility (10) . A potential explanation is that structures, which express other receptor subtypes, besides the ciliary muscle are also involved in the cholinergicmediated aqueous outflow effects. Clarification of this hypothesis requires future studies on other ocular tissues, such as the trabecular meshwork, and in vivo experiments using receptor subtype-selective agonists when they become available.
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